Kneat.com Inc T.KSI

Alternate Symbol(s): KSIOF

Healthcare Medical Devices

kneat.com, inc. develops and markets the Kneat Gx software-as-a-service (SaaS) platform. It designs, develops and supplies software for data and document management within regulated environments. The Company’s focus is to service the facilities, equipment and computer systems (CSV) validation market initially within the global life sciences industry. The Company’s product is Kneat Gx, a configurable, off-the-shelf application focused on validation lifecycle management and testing primarily within the life sciences industry. Kneat Gx provides a compliant digital solution that enables companies in the life sciences industry to become efficient and compliant with an automated process that has traditionally been manual, inefficient and paper-based. Its various validation processes include electronic logbook management, analytical instrument validation, utility and facility validation, process validation, method validation and equipment validation, cold chain validation, and others.

TSX:KSI - Post by User

Kneat.com Inc

Bullboard Posts

Post by retiredcfon Mar 27, 2020 4:00pm

266 Views

Post# 30854319

Ink Research

Morning Report: Insiders bet on pharma industry innovator

March 26, 2020

Canada's morning overview of insider filings with a special focus on companies that may interest active and momentum-oriented investors.

Canadian Company Insider Filing Tally* - Yesterday

INK Market-Wide Sentiment Indicator*

INK Market-Wide Sentiment Indicator: 405.7%
INK Sentiment Reading: Undervalued INK Venture Sentiment Reading: Undervalued

Overview: Sentiment and Stocks

The race is on among the world's pharmaceutical companies to find treatments or a vaccine for COVID-19. TSX-Venture listed kneat.com may be poised to benefit. The company provides software that allows pharmaceutical and other industries to manage their highly regulated product lifecycle and testing processes. This allows their clients to move from a cumbersome paper-based process to Kneat's software as a service platform. The company is targeting top tier pharmaceutical firms which typically enter into three-year contracts.

In fact, on Wednesday, Kneat (pronounced neat) said it signed a three-year software as a service deal with an unnamed global pharma company with more than 25,000 employees across multiple global facilities. That helped push the stock up 27.5% on the day. Nevertheless, the stock remains below the $2.10 price associated with a March 12th $14.5 million financing when the company issued just under 6.9 million shares under a prospectus and concurrent private placement. Board chair Ian Ainsworth and Director Wade Dawe were buying in the financing and again on Monday when the stock made a new 52-week low of $1.05 on heavy volume. Monday is looking more and more like it may mark a significant support level for Canadian stocks and maybe Kneat as well

Bullboard Posts

One of the strongest contenders to lead Canada’s cannabis market